Incidence Of Infections In Patients With Severe, Uncontrolled Asthma Treated With Tezepelumab: A Pooled Analysis Of The Phase 2b PATHWAY And Phase 3 NAVIGATOR Studies

Tezepelumab is a humanized monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cytokine implicated in asthma pathogenesis. This post hoc analysis describes the incidence of infection-related adverse events (AEs) in patients treated with tezepelumab, using pooled data from the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies.